Mindie H. Nguyen, MD, MAS, AGAF, FAASLD

Professor of Medicine (Gastroenterology and Hepatology) and, by courtesy, of Epidemiology and Population Health

Bio

Dr. Nguyen is Professor of Medicine, a Stanford Cancer Institute member and specializes in the treatment and prevention of primary liver cancer such as hepatocellular carcinoma (HCC).

Dr. Nguyen is also a Professor of Epidemiology and Population Health by courtesy at Stanford. Her clinical and research focus has been liver cancer for the past 20+ years. She is a frequent lecturer for the management and prevention of liver cancer for care providers and researchers at national and international conferences. She has published several key research papers to inform clinicians of the care and treatment of patients with liver cancer.

Dr. Nguyen’s clinical and research focus also include patients with cirrhosis, viral hepatitis, nonalcoholic fatty liver disease (NAFLD/NASH). Her goal is to promote early detection of liver tumors and to prevent and treat complications from chronic liver diseases and liver cancer. She has extensive experience in performing clinical trials on liver cancer, fatty liver, cirrhosis, and viral hepatitis. She has lead several multi-center US and international studies.

Dr. Nguyen is clinically active, seeing patients three full days a week, with a large and comprehensive practice of general liver, liver cancer, and transplant patients at Stanford University Medical Center, as well as weekly outreach clinics in the San Jose area.

Dr. Nguyen has served as Director of the Hepatology Fellowship Program in the Division of Gastroenterology and Hepatology and the Liver Transplant Program . Currently, she is Director of the Hepatology Clerkship, a member of Stanford Bio-X, and Stanford Population Science, a member of the Appointments and Promotions Committee and a Diversity LENS Advocate for the Department of Medicine, assisting in the promotion of equity and diversity in the professoriate search process.

Dr. Nguyen has mentored over 150 trainees of diverse racial, ethnic, and economic backgrounds and levels of training. Her research lab includes trainees who are high school students, undergraduate students, medical students, graduate students in the Master’s in Epidemiology or Public Health, PhD students in Epidemiology, clinical interns and residents, clinical gastroenterology and hepatology fellows, postdoctoral research fellows, early and mid-career faculty, and international visiting scholars. She has also served as Pre-Major Academic Advisor for the undergraduate school. Her mentees are from Stanford as well as other institutions in the US and overseas.

Dr. Nguyen is a Fellow of the American Association for the Study of Liver Diseases (AASLD) and the American Gastroenterological Association (AGA), and a member of the American College of Gastroenterology (ACG), the European Association for the Study of Liver Diseases (EASL), and the Asia Pacific Association for the Study of Liver (APASL). She is also currently the President of the International Association for the Study of Liver Diseases (IASL).

Dr. Nguyen is active in national and international professional society service and community outreach efforts locally, including service as an executive board of director for nonprofit organizations. She is very active in AASLD, having served as Chair of the Hepatitis B Special Interest Group and in the Education and Hepatology Associate Committees, as member of the Steering Committee for the Hepatobiliary Neoplasia and Hepatitis B Special Interest Group, and as a member of the Practice Guideline Committee. She is a member of the Research Award Panel for the AGA, and a member of the Practice Management Committee for the ACG.

Dr. Nguyen has served in the editorial and advisory boards for several journals, including Gastroenterology, Hepatology, Lancet GI Hepatology, and as ad hoc reviewer for over thirty scientific journals including JAMA, AIM and the Lancet Group.

Clinical Focus

Liver cancer and tumors
Hepatocellular Carcinoma
Cirrhosis
Non-alcoholic fatty liver disease
Chronic hepatitis B and C
Hepatology and Liver Transplantation
End-stage liver disease
Evaluation of abnormal liver tests
Community Outreach
Liver tumors
Transplant Hepatology

Academic Appointments

Professor - University Medical Line, Medicine - Gastroenterology & Hepatology
Professor - University Medical Line (By courtesy), Epidemiology and Population Health
Member, Bio-X
Member, Maternal & Child Health Research Institute (MCHRI)
Member, Stanford Cancer Institute

Administrative Appointments

Member, Advisory Task Force SIG, American Association for the Study of Liver Disease (AASLD) (2023 - 2025)
President, International Association for the Study of Liver Diseases (IASL) (2023 - 2025)
Steering Committee, HBV Special Interest Group, American Association for the Study of Liver Disease (AASLD) (2023 - 2025)
Steering Committee, Hepatobiliary Neoplasia Special Interest Group, American Association for the Study of Liver Disease (AASLD) (2023 - 2025)
Member Gastroenterology Editorial Board, American Gastroenterological Association (AGA) (2023 - 2024)
Associate Editor, Portal Hypertension & Cirrhosis (2022 - Present)
Chair, Abstract Review Committee, Liver and Biliary Carcinoma (Treatment, Diagnosis, Nat Hx), Digestive Disease Week (American Gastroenterological Association) (2022 - Present)
Faculty Search Diversity Advisor, Department of Medicine, Stanford University (2019 - Present)
Governing Council and Treasurer, International Association for the Study of Liver Diseases (IASL) (2019 - Present)
Practice Management Committee, American College of Gastroenterology (ACG) (2019 - Present)
Clinical Practice Guideline Committee, AASLD (2019 - 2022)
Research Award Panel, American Gastroenterological Association (AGA) (2019 - 2021)
Chair, Hepatitis B SIG, American Association for the Study of Liver Disease (AASLD) (2019 - 2020)
Chair, Global Outreach Subcommittee, Hepatitis B Special Interest Group, American Association for the Study of Liver Disease (AASLD) (2018 - Present)
International Advisory Board, Lancet Gastroenterology and Hepatology (2018 - Present)
Professoriate Appointments and Promotions Committee (DoM A&P Committee), Department of Medicine, Stanford University (2018 - Present)
International Editorial Board, Alimentary Pharmacology and Therapeutics (2018 - 2023)
Vice-Chair, Hepatitis B SIG, American Association for the Study of Liver Disease (AASLD) (2018 - 2019)
Editorial Board, Hepatology (2017 - 2019)
CIGH Faculty Fellow, Center for Innovation in Global Health (CIGH), Stanford University (2015 - Present)
Steering Committee, HBV Special Interest Group, American Association for the Study of Liver Diseases (AASLD) (2015 - Present)
Director of Hepatology Fellowship, http://med.stanford.edu/gastrohepfellows/, Stanford University Medical Center (2014 - Present)
Steering Committee, Hepatobiliary Neoplasia Special Interest Group, American Association for the Study of Liver Diseases (AASLD) (2014 - 2016)
Director of Hepatology Clerkship, Stanford University School of Medicine (2013 - Present)
Executive Board of Director, Asian Health Foundation (2013 - Present)
Liver Section Editor, Journal of Clinical Gastroenterology (2013 - Present)
Medical Advisory Board, American Liver Foundation (2013 - Present)
Committee Chair, Abstract Review for Chronic Hepatitis B, American Association for the Study of Liver Diseases (AASLD) (2013 - 2019)
Education Committee, American Association for the Study of Liver Diseases (AASLD) (2013 - 2016)
Hepatology Associates Committee , MD Liaison, American Association for the Study of Liver Diseases (AASLD) (2013 - 2016)
Editorial Board, Gastroenterology (2011 - Present)
Abstract review member for the Hepatitis B : Epidemiology/Prevention/Control review group, American Association for the Study of Liver Diseases (AASLD) (2011 - 2016)
Editorial Board, Digestive Diseases and Sciences (2008 - Present)
Director of Continuing Medical Education, Pacific Health Foundation (2005 - 2012)
Director of Clinical Research, Pacific Health Foundation (2004 - Present)
Training and Workforce Committee, Member, American Association for the Study of Liver Diseases (AASLD) (2002 - 2004)

Honors & Awards

The Professor Mindie H. Nguyen Award for Excellent Clinical Research by Young Investigators, The American Association for the Study of Liver Diseases (AASLD) (2020-2031)
Senior Fellow at the Center for Innovation in Global Health, Center for Innovation in Global Helath, Stanford University, Stanford, CA (2015 Oct)
Stanford Asian American Faculty Awards, The Asian American Activities Center, Stanford University, Stanford, CA (2015 May)
2015 Divisional Teaching Award, Department of Medicine, Stanford University Medical Center, Palo Alto, CA (2015 Dec)
Pacific Free Clinic Physician Service Award, Cardinal Free Clinics, Stanford University School of Medicine (2013 April)
The Franklin Edbaugh Advising Award for Faculty, Stanford University School of Medicine (2013 May)
Chief Fellow in Gastroenterology and Hepatology, Stanford University Medical Center (2002)
Advanced Hepatology Research Fellow Award, American Association for the Study of Liver Diseases (2001)
Chief Resident, University of California, San Diego Medical Center (1996)
Excellence in Teaching Award, University of California, San Diego, School of Medicine (1996)
Magna Cum Laude, University of California, Irvine (1988)
Phi Beta Kappa, University of California, Irvine (1985)

Boards, Advisory Committees, Professional Organizations

See Administrative Appointment Section above, See above (2013 - Present)

Professional Education

Board Certification: American Board of Internal Medicine, Gastroenterology (2020)
Fellowship: Stanford University Gastroenterology Fellowship (2002) CA
Residency: UCSD Internal Medicine Residency (1995) CA
Medical Education: University of California San Diego School of Medicine (1992) CA
Board Certification, American Board of Internal Medicine, Gastroenterology (2018)
Board Certification: American Board of Internal Medicine, Transplant Hepatology (2010)
B.S., University of California, Irvine, Biological Sciences (1988)
M.D., Univ. of California, San Diego, Medicine (1992)
M.A.S., Univ. of Calif., San Francisco, Masters of Advanced Studies in Clinical Research (2004)

Community and International Work

Governning Council

Topic

Partnering Organization(s)

International Association for the Study of Liver Diseases

Populations Served

Location

Ongoing Project

true

Opportunities for Student Involvement

false
Board of Directors

Topic

Partnering Organization(s)

Pacific Health Foundation

Populations Served

Location

Bay Area

Ongoing Project

false

Opportunities for Student Involvement

false
Board of Directors

Topic

Partnering Organization(s)

Asian Health Foundation

Populations Served

Location

US

Ongoing Project

false

Opportunities for Student Involvement

false
Scientific Chair, Myanmar Liver Symposium 2018, Yangon

Topic

Viral Hepatitis and Liver Cancer

Partnering Organization(s)

Myanmar Ministry of Health&Sports and BK Kee Foundation

Populations Served

Physicians and Public Health Workers

Location

International

Ongoing Project

true

Opportunities for Student Involvement

true
Scientific Chair, Health Needs Assessment and Liver Symposium, Yangon

Topic

Updates in Viral Hepatitis and Liver Cancer

Partnering Organization(s)

Myanmar Ministry of Health Sports, BK Kee Fdn, Stanford Global Health

Populations Served

Burmese

Location

International

Ongoing Project

true

Opportunities for Student Involvement

true
Scientific Chair, Viral Hepatitis and Liver Cancer 2015: Mongolia National Training Workshop

Topic

Partnering Organization(s)

Mongolian Ministry of Health

Populations Served

Physicians

Location

International

Ongoing Project

false

Opportunities for Student Involvement

false
Linkage to care, epidmiology of hepatitis B, hepatitis C, and/or liver cancer in Asia Pacific region, Mainland China, South Korea, Taiwan, Hong Kong, Japan, New Zealand, Myanmar

Topic

Partnering Organization(s)

Populations Served

Location

International

Ongoing Project

true

Opportunities for Student Involvement

true
Pacific Free Clinic

Topic

Hepatology Clinic

Partnering Organization(s)

Populations Served

Location

Bay Area

Ongoing Project

false

Opportunities for Student Involvement

false
Outreach Liver Clinics, San Jose and San Francisco, San Jose, 231 O'Connor Drive and 200 Jose Figueres Avenue; San Francisco and Daly city

Topic

Partnering Organization(s)

Populations Served

Patients with liver disease

Location

International

Ongoing Project

true

Opportunities for Student Involvement

false
Epidemiology and treatment outcomes of Asian patients with chronic hepatitis B and C, San Jose, CA and Dallas, Texas

Topic

Ethnic differences of disease activities, treatment, and outcomes in Asian Americans

Partnering Organization(s)

Pacific Health Foundation

Populations Served

Asian Americans

Location

International

Ongoing Project

true

Opportunities for Student Involvement

true
Colon cancer screening in Asian Americans, San Jose

Topic

Partnering Organization(s)

Pacific Health Foundation

Populations Served

Asian Americans

Location

Bay Area

Ongoing Project

true

Opportunities for Student Involvement

true
Updates in Hepatology, Vietnam

Topic

Partnering Organization(s)

University of Michigan and Vietnamese Association for the Study of Liver Diseases

Populations Served

Vietnamese Hepatologists

Location

International

Ongoing Project

false

Opportunities for Student Involvement

false

Contact

Clinical (Primary)

This is the primary clinic for this clinical provider. For additional clinical locations and information, please visit the link(s) listed below in the 'Additional Clinical Info' section.

Stanford Gastroenterology and Digestive Health Clinic 420 Broadway St Pav D 2nd Fl Pod 2 and 3 Redwood City CA 94063 Tel: (650) 498-7999 Fax: (650) 724-9454

Additional Clinical Info

Current Research and Scholarly Interests

1. Clinical trials in fatty liver (NASH/NAFLD), liver cancer (HCC), hepatitis B and hepatitis C.
2. Epidemiology and population health of people with liver cancer, fatty liver, hepatitis B, hepatitis C, and liver cirrhosis.
3. Real-world studies of liver cancer, fatty liver, hepatitis B, hepatitis C,liver cirrhosis, and liver transplant.
4. Health disparities - sex differences, socioeconomic factors, and race/ethnicity-related issues
5. Translational studies of liver cancer, hepatitis B, and fatty liver.
6. Global health: medical education, public health, and research. Areas with current/prior work/collaboration: Spain, Romania,United Kingdom, Germany, Italy, Argentina, Brazil, Japan, Australia, New Zealand, Mainland China, Taiwan, Hong Kong, South Korea, Mongolia, Myanmar, Thailand, and Singapore.
7. Large databases used in prior published works: U.S. National Health and Nutrition Examination Survey (NHANES), Optum, Truven, Surveillance Epidemiology and End Results (SEER), UK Biobank, American Census Bureau, National Death Index (NDI), National Vital Statistic System (NVSS) from the CDC WONDER platform, National Inpatient Sample Database (NIS), United Network for Organ Sharing (UNOS), California inpatient database from the Office of Statewide Health Planning and Development (OSPHD), Taiwan National Health Insurance Research Database (NHIRD), Japan Medical Data Vision Database, Korea Health Insurance Review & Assessment Service Database (HIRA).

For more information, please contact my lab at 650-498-6084.

Clinical Trials

Clinical Trial Multi-analyte Blood Test Recruiting
More
This is a clinical trial designed to evaluate the performance of a multi-analyte blood test alone, ultrasound alone and the combination of both the multi-analyte blood test and ultrasound for the detection of HCC within a population that is at high risk for HCC due to liver cirrhosis.
Lead Sponsor
Stanford Investigators
- Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
View full details
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk Recruiting
More
The primary objective is to assess overall sensitivity and specificity of Oncoguard™ Liver for hepatocellular cancer (HCC) detection in a surveillance population.
Lead Sponsor
Stanford Investigators
- Tyler Johnson
- Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
View full details
Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA) Recruiting
More
The study aims to evaluate two, orally administered, investigational agents - PF-06865571 (DGAT2 inhibitor) and the coadministration of PF-06865571 with PF-05221304 (ACC inhibitor). This study is specifically designed to evaluate the effect of a range of doses of DGAT2i alone, and DGAT2i + ACCi, on resolution of NASH or improvement in liver fibrosis, as assessed histologically (via liver biopsy).
Lead Sponsor
Stanford Investigators
- Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
View full details
Case-Control Study of the Glycotest™ HCC Panel vs AFP for the Detection of Early-stage Hepatocellular Carcinoma Not Recruiting
More
Clinical guidelines (AASLD) recommend the use of abdominal ultrasound (US) for surveillance testing for the early detection of Hepatocellular Carcinoma (HCC). The serum protein biomarker alpha-fetoprotein (AFP) is commonly used to augment US but its use alone is not recommended by clinical guidelines. Despite evidence that HCC surveillance improves early detection and reduces mortality from HCC, current HCC surveillance tests lack sensitivity, leaving a significant proportion of patients to present with late-stage disease. The Glycotest HCC Panel has shown better sensitivity than AFP, which is ineffective for the detection of early-stage HCC. This clinical study seeks to validate the Glycotest HCC Panel using a large multicenter cohort of cases and controls that includes patients diagnosed with early-stage HCC against a background of cirrhosis and cirrhotic patients without HCC (at risk) undergoing an established surveillance protocol.

Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Lead Sponsor
Stanford Investigators
- Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
View full details
Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide (TAF) Not Recruiting
More
Primary Objective: To describe rate of persistence and/or improvement of viral suppression with TAF as with previous anti-HBV (hepatitis B virus) treatment

Stanford is currently not accepting patients for this trial. For more information, please contact Mindie H Nguyen, MD,MAS, 650-736-1731.

Lead Sponsor
- Stanford University
Stanford Investigators
- Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
View full details
Gilead Sustained Virologic Response (SVR) Registry Not Recruiting
More
This Registry is designed to provide long term clinical and virologic follow up in participants who have achieved sustained virologic response (SVR) while participating in a previous Gilead sponsored hepatitis C virus (HCV) study. This long term follow up study is observational and no treatment is provided for HCV.

Stanford is currently not accepting patients for this trial. For more information, please contact Mindie H. Nguyen, MD, 650-498-7878.
Lead Sponsor
Stanford Investigators
- Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
View full details
Risk Factors and Molecular Genomics of U.S. Patients With Chronic Liver Disease and Hepatocellular Cancer Not Recruiting
More
To identify risk factors for the development and diagnosis of hepatocellular CA in patients with chronic hepatitis C and to use the data to ultimately develop an effective screening program.

Stanford is currently not accepting patients for this trial. For more information, please contact Andrea Linder, 6507254047.

Lead Sponsor
- Stanford University
Stanford Investigators
View full details
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV Not Recruiting
More
The purpose of this study is to evaluate the safety, tolerability, and antiviral efficacy of ledipasvir (LDV)/sofosbuvir (SOF) fixed-dose combination (FDC) tablets with or without ribavirin (RBV) administered for 12 and 24 weeks in treatment-naive subjects with chronic genotype 1 HCV infection.

Stanford is currently not accepting patients for this trial. For more information, please contact Mindie H. Nguyen, MD, 650-498-7878 .
Lead Sponsor
Stanford Investigators
- Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
View full details
Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma Not Recruiting
More
Primary Objective: To compare the efficacy of TACE vs. CyberKnife SBRT in the treatment of locally recurrent HCC after initial TACE. Secondary Objectives: 1. To determine the progression-free survival of TACE vs. CyberKnife SBRT 2. To determine the overall survival of TACE vs. CyberKnife SBRT for locally recurrent HCC 3. To determine the toxicities associated with TACE or CyberKnife SBRT for the treatment of recurrent HCC.

Stanford is currently not accepting patients for this trial. For more information, please contact Laurie Ann Columbo, 6507360792.
Lead Sponsor
Stanford Investigators
View full details
Safety, Tolerability, and Efficacy of 24 Weeks Simeprevir+Sofosbuvir for Chronic Hepatitis C Genotype 1 Not Recruiting
More
The goal of this pilot study is to examine both efficacy and tolerability in patients with HCV genotype 1 and mild decompensation with Child-Pugh-Turcott score of 6 or lower. The CPT score is used to assess the prognosis of chronic liver diseases, as well as the required strength and treatment and necessity of liver transplantation. A higher CPT score denotes higher necessity of liver transplantation.

Stanford is currently not accepting patients for this trial. For more information, please contact Mindie H Nguyen, MD, MAS, 650-498-5691.

Lead Sponsor
- Stanford University
Stanford Investigators
- Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
View full details
Comparative Efficacy of Fixed-dose Combination Sofosbuvir + Ledipasvir, 8 vs. 12 Weeks in Chronic Hepatitis C Genotype 6 Not Recruiting
More
The primary objectives of this study are to describe the efficacy of: 1. 8-week treatment of SOF/LED for treatment-naïve, non-cirrhotic, HCV genotype 6 2. 12-week treatment of SOF/LED for all other HCV-6 populations

Stanford is currently not accepting patients for this trial. For more information, please contact Mindie H Nguyen, MD, MAS, 650-498-5691.

Lead Sponsor
- Stanford University
Stanford Investigators
- Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
View full details
Epidemiologic Study of Hepatocellular Carcinoma in the US Not Recruiting
More
The purpose of this study is: - to investigate the risk factors of HCC among Americans with focus on lifestyle factors and energy balance. - to identify single nucleotide polymorphisms (SNPs) and haplotypes that are associated with HCC risk through a genome-wide search. - to assess if genetic susceptibility differs by hepatitis virus infection or lifestyle factors, and to explore if there are interplays or effect modifications between genetic factors and viral infection or lifestyle factors.

Stanford is currently not accepting patients for this trial. For more information, please contact Pauline Nguyen, .

Lead Sponsor
- Stanford University
Stanford Investigators
- Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
View full details
Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Positive for Hepatitis B e Antigen Not Recruiting
More
The primary objective of this study is to compare the efficacy, safety, and tolerability of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in treatment-naive and treatment-experienced adults with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B virus (HBV) infection.

Stanford is currently not accepting patients for this trial. For more information, please contact SPECTRUM, 650-498-6474.
Lead Sponsor
Stanford Investigators
- Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
View full details
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection Not Recruiting
More
This study is to evaluate the safety, tolerability, and antiviral efficacy of ledipasvir/sofosbuvir fixed dose combination (FDC) with or without ribavirin (RBV) administered for 12 or 24 weeks in treatment-experienced subjects with chronic genotype 1 hepatitis C virus (HCV) infection.

Stanford is currently not accepting patients for this trial. For more information, please contact Mindie H. Nguyen, MD, 650-498-7878.
Lead Sponsor
Stanford Investigators
- Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
View full details
Registry Study for Patients With Chronic HBV Receiving Nucleotide Therapy Not Recruiting
More
This registry will remain open for approximately 5 years (4 years of enrollment + 1 year of follow up). Subjects will be followed until Orthotopic Liver Transplant (OLT), resolution of liver decompensation, death, or conclusion of the registry.

Stanford is currently not accepting patients for this trial. For more information, please contact Mindie Nguyen, 650-497-6474.
Lead Sponsor
Stanford Investigators
- Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
View full details
Hepatitis B Virus (HBV) Viral Suppression by Entecavir in Adefovir Partial Responders Not Recruiting
More
We propose a largely retrospective study with short-term prospective follow-up in a subgroup of patients who have not yet been treated with 48 weeks of entecavir following partial response to adefovir. The aim of the study is to describe sequential virologic response to adefovir and entecavir.

Stanford is currently not accepting patients for this trial. For more information, please contact Mindie H. Nguyen, MD, 650-498-7878.
Lead Sponsor
Stanford Investigators
- Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
View full details
GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection Not Recruiting
More
The purpose of this phase 2 study is to determine whether 30 mg or 90 mg of GS-5885 when given with GS-9451, Tegobuvir and Ribavirin (RBV) for 12 or 24 weeks is effective, safe and tolerable in the treatment of Chronic Genotype 1 HCV Infection.

Stanford is currently not accepting patients for this trial. For more information, please contact Mindie H Nguyen, MD, 650-498-7878.
Lead Sponsor
Stanford Investigators
- Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
View full details
Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005) Not Recruiting
More
Parts A and B of this study are designed to evaluate the safety, tolerability, efficacy and pharmacokinetic profiles of samatasvir and simeprevir when administered in combination with ribavirin (RBV) for 12 weeks in treatment-naïve, Genotype (GT) 1b, 4 and 6 hepatitic C virus (HCV)-infected participants. Part C of this study is designed to evaluate the safety, tolerability, efficacy and pharmacokinetic profiles of samatasvir, simeprevir, TMC647055 and ritonavir (RTV) when administered in combination with or without RBV for 12 weeks in treatment-naïve or interferon/RBV-treatment relapsed, GT 1a and 1b HCV-infected participants.

Stanford is currently not accepting patients for this trial. For more information, please contact SPECTRUM, 650-497-6474.
Lead Sponsor
Stanford Investigators
- Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
View full details
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response Not Recruiting
More
This Registry is designed to obtain long term data on participants who have failed to achieve sustained virologic response (SVR) while receiving at least one Gilead oral antiviral agent (OAV) in a previous Gilead-sponsored hepatitis C virus (HCV) study.

Stanford is currently not accepting patients for this trial. For more information, please contact Mindie H. Nguyen, MD, 650-498-7878.
Lead Sponsor
Stanford Investigators
- Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
View full details
Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia Not Recruiting
More
The primary objective for this study is to evaluate the proportion of subjects who achieve SVR12 (HCV RNA < LLOQ (target not detected) at post-treatment follow-up Week 12 in subjects with Genotype(GT)-1b, -4 and GT-2, -3

Stanford is currently not accepting patients for this trial. For more information, please contact Mindie H. Nguyen, MD, 650-498-7878.
Lead Sponsor
Stanford Investigators
- Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
View full details
Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis B Not Recruiting
More
The primary objective of this study is to evaluate the efficacy of tenofovir disoproxil fumarate (TDF) plus peginterferon α-2a (Peg-IFN) combination therapy for 48 weeks versus standard of care TDF monotherapy or Peg-IFN monotherapy for 48 weeks in non-cirrhotic adults with chronic hepatitis B virus (HBV) as determined by loss of hepatitis B surface antigen (HBsAg). The study will consist of 2 phases for participants in the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups. Following an initial 48 weeks of treatment, participants in these groups will be monitored for 24 weeks for signs of worsening HBV, and those meeting TDF retreatment and flare management criteria will be eligible to receive TDF monotherapy during a retreatment phase, up to Week 120.

Stanford is currently not accepting patients for this trial. For more information, please contact Mindie Nguyen, MD, 650-498-7878.
Lead Sponsor
Stanford Investigators
- Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
View full details
Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C Not Recruiting
More
This study will assess the rates of Sustained Virological Response following anti-viral therapy with Peg-Interferon plus Ribavirin in patients that have been liver transplanted with recurrent Hepatitis C and treated with Neoral or tacrolimus.

Stanford is currently not accepting patients for this trial. For more information, please contact Mindie Nguyen, MD, 650-498-7878.
Lead Sponsor
Stanford Investigators
- Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
View full details
Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects Not Recruiting
More
This study is to evaluate the safety, tolerability, and antiviral efficacy of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) with or without ribavirin (RBV), administered for 8 or 12 weeks of treatment in participants with chronic genotype 1 hepatitis C virus (HCV) infection who are treatment-naive, and for 12 weeks in participants who had previously received a regimen containing a protease inhibitor for the treatment of HCV.

Stanford is currently not accepting patients for this trial. For more information, please contact Mindie H Nguyen, 650-498-7878.
Lead Sponsor
Stanford Investigators
- Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
- Terry Robinson
View full details
Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e Antigen Not Recruiting
More
The primary objective of this study is to compare the efficacy, safety, and tolerability of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in treatment-naive and treatment-experienced adults with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B virus (HBV) infection.

Stanford is currently not accepting patients for this trial. For more information, please contact SPECTRUM, 650-498-6084.
Lead Sponsor
Stanford Investigators
- Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
View full details
Evaluation of Stereotactic Radiosurgery For Liver Malignancies Not Recruiting
More
This study is intended to establish the practicality of treating cancer in the liver with precisely administered single fractions of high-energy radiation using a radiosurgical (cross-firing) technique. A second purpose is to establish a safe dose for such therapy. Finally, the efficacy of radiosurgical ablation of liver tumors, in terms of radiographic response, will be measured.

Stanford is currently not accepting patients for this trial. For more information, please contact Jeff Kim, 6504987703.

Lead Sponsor
- Stanford University
Stanford Investigators
View full details

2023-24 Courses

Independent Studies
- Directed Reading in Epidemiology
  EPI 299 (Aut, Win, Spr)
- Directed Reading in Medicine
  MED 299 (Aut, Win, Spr, Sum)
- Early Clinical Experience in Medicine
  MED 280 (Aut, Win, Spr, Sum)
- Graduate Research
  EPI 399 (Aut, Win, Spr, Sum)
- Graduate Research
  MED 399 (Aut, Win, Spr, Sum)
- Medical Scholars Research
  MED 370 (Aut, Win, Spr, Sum)
- Out-of-Department Undergraduate Research
  BIO 199X (Aut, Win, Spr)
- Undergraduate Research
  EPI 199 (Aut, Win, Spr)
- Undergraduate Research
  MED 199 (Aut, Win, Spr, Sum)

Stanford Advisees

Postdoctoral Faculty Sponsor
Xinrong Zhang
Master's Program Advisor
Camille Goenawan, Patil Kavarian
Postdoctoral Research Mentor
Xinrong Zhang

Graduate and Fellowship Programs

Epidemiology (Masters Program)
Epidemiology (Phd Program)
Gastroenterology & Hepatology (Fellowship Program)

All Publications

Profiles With Related Publications

close
Ranjana Advani

Saul A. Rosenberg, MD, Professor of Lymphoma
Clinical Focus
Cancer > Lymphoma, Burkitt's Lymphoma, Hodgkin's Disease, Investigational Therapeutics, Lymphoma , Mycosis Fungoides, Non-Hodgkin's Lymphoma, Oncology (Cancer), Plasmacytoma, Waldenstrom's Macroglobulinemia , Medical Oncology
Research Interests
Clinical investigation in Hodgkin's disease, non-Hodgkin's Lymphomas and cutaneous lymphomas. Experimental therapeutics with novel chemotherapy and biologically targeted therapies.

The research program is highly collaborative with radiation oncology, industry, pathology and dermatology.

664 Total Publications
close
Steven Asch

Professor of Medicine (Primary Care and Population Health) and, by courtesy, of Health Policy
Research Interests
Describe your current research interest and activities

597 Total Publications
close
Sierra Mei Lin Centkowski, MD

Clinical Assistant Professor, Dermatology
Clinical Focus
Acne, Atopic Dermatitis, Dermatologic surgery, General Dermatology, Psoriasi, Skin cancer, Dermatology

8 Total Publications
close
Stephanie D. Chao, MD FACS FAAP

Associate Professor of Surgery (Pediatric Surgery)
Clinical Focus
Pediatric Surgery, Pediatric Trauma, Chest Wall Deformities, Neonatal Surgery, Minimal Access Surgery, Adolescent Weight Management and Bariatric Surgery, Congenital Diaphragmatic Hernia, Pediatric Biliary Disease, Anorectal Malformations
Research Interests
Dr. Chao is passionate about disease prevention as she believes it is the ultimate way to impact the health of a population. Surgeons often see the devastating, end-results of the failure of prevention. With this perspective, Dr. Chao believes that it is crucial for surgeons to be active in prevention research. Dr. Chao currently serves as Trauma Medical Director of Lucile Packard Children’s Hospital and focuses much of her research on injury prevention.

65 Total Publications
close
Ramsey Cheung

Professor of Medicine (Gastroenterology and Hepatology)
Research Interests
Dr. Cheung's research interests focus on liver diseases, with emphasis on viral hepatitis. His past research include investigating the mechanism of viral neutralization of hepatitis B virus at the molecular level and immune response to hepatitis C virus. Dr. Cheung is studing various aspects of hepatitis C, both clinical and translational research.

351 Total Publications
close
Tami Daugherty

Clinical Associate Professor, Medicine - Gastroenterology & Hepatology
Clinical Focus
Hepatology, Transplant Hepatology, Gastroenterology
Research Interests
Dr. Daugherty is a transplant Hepatologist with full-time clinical responsibilities. She is particularly interested in the natural course and management of recurrent Hepatitis C after liver transplant, and the effect of immunosuppression on HCV recurrence.

44 Total Publications
close
Renumathy Dhanasekaran

Assistant Professor of Medicine (Gastroenterology)
Clinical Focus
Liver cancer, Liver translant, Hepatology, Gastroenterology
Research Interests
The overall goal of my research is to understand the molecular pathogenesis of liver cancer and identify biologically relevant prognostic biomarkers and molecular targets for therapy in patients with hepatocellular carcinoma (HCC). My long-term objective is to improve the clinical outcome of patients with liver cancer.

173 Total Publications
close
Jessica Ferguson

Clinical Assistant Professor, Medicine - Infectious Diseases
Clinical Focus
Immunocompromised Host, Infectious Disease

10 Total Publications
close
Gabriel Garcia, MD

Professor of Medicine (Gastroenterology and Hepatology) at the Stanford University Medical Center, Emeritus
Research Interests
The natural history of common viral liver diseases of man is poorly understood, despite the fact that chronic liver diseases of man may result in death from liver failure or hepatocellular carcinoma.

48 Total Publications
close
Steven Goodman

Professor of Epidemiology and Population Health, of Medicine (Primary Care and Population Health) and, by courtesy, of Health Policy
Research Interests
I am interested in issues relating to the representation and measurement of evidence in medical research, and determinants of the truth of medical findings, using a Bayesian framework. I also do work in evidence synthesis, comparative effectiveness research, and the ethics of clinical research.

235 Total Publications
close
Edith Ho

Clinical Associate Professor, Medicine - Gastroenterology & Hepatology
Clinical Focus
Gastroenterology, Inflammatory Bowel Disease, Ulcerative colitis, Crohn's Disease, Pouchitis

36 Total Publications
close
Mark Holodniy

Professor of Medicine (Infectious Diseases)
Research Interests
My research program is currently focused in three areas: 1) Translational research (viral evolution and antiviral resistance prevalence and development), 2) Clinical trials (diagnostic assay/medical device, antimicrobials and immunomodulators), and 3) Health services research focusing on public health, infectious diseases and clinical outcomes.

323 Total Publications